Instructions and instructions for tenofovir alafenamide fumarate tablets (Vemlidy)

Tenofovir alafenamide tablets (Vemlidy/Vemlidy) is a new hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor, which has high efficiency in inhibiting HBV replication and good tolerance. It is approved for the treatment of adults and pediatric patients 12 years and older with HBV infection and compensated liver disease, and is currently one of the commonly used oral antiviral drugs in the long-term management of chronic hepatitis B. Its drug mechanism mainly inhibits viral reverse transcriptase activity, thereby preventing viral DNA synthesis, thereby controlling viral replication and reducing liver inflammatory response.

1. The recommended dose is Oral administration 25 mg once a day, which can be taken with food to improve drug absorption and tolerance. Taking the drug at a fixed time every day can keep the blood concentration stable, thereby ensuring the antiviral effect.

2. Before starting to use it, you should evaluate whether the patient is infected with HIV (HIV), because HIV-infected patients should not use tenofovir alafenamide tablets alone to avoid the risk of single-drug antiviral resistance. For patients with co-infections, a combined antiviral regimen should be selected under the guidance of a professional doctor.

3. Renal function monitoring should be carried out before and during treatment, including serum creatinine, estimated creatinine clearance, urine glucose and urine protein and other indicators. For patients with chronic kidney disease, serum phosphorus levels also need to be paid attention to to prevent hypophosphatemia and abnormal bone metabolism. It is not recommended for patients with renal insufficiency (estimated creatinine clearance less than 15 mL/min) before receiving hemodialysis; for patients receiving hemodialysis, the drug should be taken after the dialysis is completed on the day of dialysis without dosage adjustment.

4. Patients with liver dysfunction should be used with caution. For patients with decompensated liver function impairment (Child-Pugh class B or C), the use of this product is not recommended; for patients with compensated liver disease, it needs to be used after evaluation of liver function and safety under the guidance of a doctor.

5. During the use of this product, liver function, kidney function and virological indicators should be monitored regularly to ensure the therapeutic effect and detect potential adverse reactions as early as possible. The drug was well tolerated, but long-term treatment still requires attention to possible renal or bone metabolic effects.

Tenofovir alafenamide fumarate tablets have become a convenient choice for the management of chronic hepatitis B due to their once-daily, small dose, and good tolerability. It emphasizes safety monitoring and individualized management in clinical use, especially for patients with renal function, liver function and concurrent infections. Through standardized drug use and regular follow-up, it can be effectively controlled during long-term antiviral treatment HBV replication, reducing the risk of liver fibrosis progression, and improving patient quality of life. In addition, its fixed dose and good oral absorption characteristics enable relatively high patient compliance and are suitable for long-term chronic management.

Generally speaking, as an important part of modern hepatitis B antiviral drugs, the instructions for Veride clearly clarify the indications for use, dosage regimen, and management requirements for special groups, providing a scientific and operable medication guide for clinical use. Patients should follow medical advice during use and regularly check liver and kidney function and viral indicators to ensure drug safety and maximize treatment effects.

Reference materials:https://www.vemlidyhcp.com/